Hemispherx Biopharma, Inc. (AMEX:HEB) previously reported that its six-year litigation battle with the South African investment conglomerate JCI Ltd., traded on the Johannesburg Stock Exchange, ended in victory August 11, 2010, with the entry of a $188 million judgment in Hemispherx’s favor and against Johannesburg Consolidated Investments (JCI) and former JCI officers R.B. Kebble and H.C. Buitendag. Kebble and Buitendag used JCI Ltd. to pull off what South African authorities have called the largest financial fraud in that country’s history, engaging in numerous acts of securities fraud. As stated in Hemispherx’s complaint, this included the illegal attempt to take over and pillage Hemispherx.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’ flagship products include Alferon N Injection(tm) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(r) and Alferon LDO(tm). Ampligen(r) represents experimental nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx’ platform technology includes agents for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(tm).
Delivery Technology Solutions, Inc. (DTSL.PK) is the leader in providing comprehensive custom-developed catering/delivery solutions to industries throughout North America, including restaurants, retail and others. The company’s solutions offer a seamless system that integrates Customer Relationship Management (CRM) and Call Center IT services through a proprietary technology backbone to offer convenience, consistent quality, flexibility, accountability and value for consumers and companies.
DTSL recently completed participation at one of the largest restaurant franchisee conventions. Its UDS division attended the convention by invitation of the leading franchisor, and was able to showcase its large corporate catering and event management delivery technology platform to many of the thousands of convention attendees, and a range of other potential partners in the industry and associated industries.
Over the three-day event the company was successful in signing up franchisees that own thousands of locations, and multiple-territory development agents who represent thousands more. Qualified franchisees are enrolled in the optional programs, and then UDS proprietary software is implemented at their unit, so orders may be received from the UDS Call Center and Online Ordering technology.
The UDS Division is already planning for a larger role in next year’s convention, due to the volume of responses expressed by this year’s attendees, and the warm welcome that was received within the vendor community. While currently in expansion of its in-house sales and marketing department, UDS is expecting to implement up to 1,500 locations before the end of 2010, and many more in 2011.
Furthermore, Mr. Smith revealed that DTSL expects to realize a 100% revenue increase in Q3 over Q2 of this year, and another 100% increase in Q4 over Q3. He forecasted 2010 revenue at $400,000 to $500,000, with 2011 revenue expected to more than double this year’s total.
In addition, DTSL main subsidiary Universal Delivery Solutions Inc. have updated the public on company business developments using Go800 “Ticker Service.” In this initial investor message, DTSL briefly introduced the company’s business model in the $33.3 billion catering and management planning business sector. DTSL also introduced several major business agreements, including the major nationwide deal with the #1 national sub sandwich chain in the US, and an agreement with the largest movie chain with 1400 theatres for their catering needs.
For more information about this company please visit http://www.universaldelivery.com/
Continucare Corp. (AMEX:CNU) continues its run of acquisitions with the purchase Precision Diagnostic Services and SleepEasy Therapeutics.
The Miami-based company recently purchased the related entities in North Dakota through its Seredor Corp. subsidiary. The deal adds 47 sleep diagnostic centers in eight states, with 44 based in hospitals. It also sells continuous positive airway pressure devices.
Continucare Corporation, together with its subsidiaries, provides primary care physician services on an outpatient basis in the United States. It provides medical services to patients through physicians, nurse practitioners, and physician?s assistants. The company also provides practice management services, including assistance with medical utilization management, pharmacy management, and specialist network development to independent physician affiliates (IPAs).
Cortex Pharmaceuticals Inc. (NYSE:COR) recently announced the underwriters’ full exercise of their over-allotment option to purchase an additional 2,535,000 shares of the Company’s common stock at a public offering price of $16.00 per share, less the underwriting discounts and commissions. The over-allotment option was granted pursuant to an underwriting agreement executed in connection with the Company’s initial public offering of 16,900,000 shares, which was priced on September 22, 2010.
The initial public offering, including the purchase of the shares pursuant to the exercise of the overallotment option, is expected to close on September 28, 2010.
CoreSite Realty Corporation is an owner, developer and operator of strategically located real estate, designed to meet the stringent needs of the information technology community. The Company offers private data centers and suites, cage-to-cabinet colocation, and interconnection opportunities, including the Any2 public peering exchange.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
PLEASE BE SURE TO VISIT CRWESELECT.NING.COM
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received twenty-five thousand dollars in cash from a third party (Ceiba Network/PenStox) for (30) days of advertising for Delivery Technology Solutions, Inc. (DTSL.PK).